GOOD MORNING

Here’s everything you need to know today: There are currently 14,157 publicly traded companies in the United States and over 1000+ articles released about S&P500 companies alone every single day. Today we will be showing you our top 3 stock picks we have hand picked for this week:

1 year performance

1. V - 21%

2. COST - 31%

3. SMMT - 475%

This Week (Here’s our top 3 stock picks)  

1. Visa Inc. (V)

1 Year Performance: +21%

Category: Growth

Market Cap: $651B

Company Info:

Visa Inc. is a global digital payments technology company that facilitates electronic fund transfers between consumers, merchants, financial institutions, and government entities across more than 200 countries and territories. Operating through its secure transaction processing network, VisaNet, the company enables the authorization, clearing, and settlement of payment transactions, supporting a wide range of payment methods including credit, debit, and prepaid cards.

Why it’s a buy:

Visa Inc. (NYSE: V) presents a compelling investment opportunity due to its robust financial performance, strategic growth initiatives, and strong market position in the digital payments industry.

In fiscal year 2024, Visa reported net revenue of $35.9 billion, a 10% increase from the previous year, and net income of $19.7 billion, up 14% year-over-year. The company processed 233.8 billion transactions, reflecting a 10% increase, and achieved a payments volume of $13.2 trillion.

Visa's expansion into commercial payments and value-added services, coupled with its significant investments in technology and AI, positions it well for sustained growth.

Additionally, the company's commitment to shareholder returns is evident through its consistent dividend growth and share repurchase programs. These factors collectively suggest that Visa is well-positioned for continued success in the evolving digital payments landscape.

Revenue:

2. Costco Wholesale Corp. (COST)

1 Year Performance: +31%

Category: Growth

Market Cap: $427B

Company Info:

Costco Wholesale Corporation is a global membership-based warehouse retailer that offers a wide range of brand-name and private-label products at low prices, primarily through its bulk sales model. Operating over 800 warehouses worldwide, Costco generates significant revenue from its membership fees, which support its strategy of maintaining low product markups and delivering value to customers.

Why it’s a buy:

Costco Wholesale Corporation (NASDAQ: COST) stands out as a compelling investment opportunity due to its resilient business model, consistent financial performance, and strategic growth initiatives. In fiscal year 2024, Costco reported revenue of $254.45 billion, a 5.02% increase from the previous year, and net income of $7.37 billion, up 17.09% year-over-year.

The company’s March 2025 sales rose 8.6% year-over-year to $25.5 billion, with same-store sales up 6.4% and e-commerce sales increasing 16%, indicating strong consumer demand across channels. Costco's membership-based model, characterized by high retention rates and recurring revenue, provides a stable income stream.

Additionally, its plans to open 33 new locations in fiscal 2025 demonstrate a commitment to expansion and market penetration. Despite potential headwinds like tariff-related price increases, Costco’s efficient supply chain and strong supplier relationships position it well to maintain its value proposition.

These factors collectively suggest that Costco is well-positioned for sustained growth and long-term value creation in the evolving retail landscape.

Revenue:

3. Summit Therapeutics Inc. (SMMT)

1 Year Performance: +475%

Category: Momentum

Market Cap: $17.1B

Company Info:

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies addressing serious unmet medical needs, particularly in oncology and infectious diseases. Headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, UK, Summit's lead candidate, ivonescimab, is a bispecific antibody currently in Phase III clinical trials for non-small cell lung cancer, developed in collaboration with Akeso, Inc.

Why it’s a buy:

Summit Therapeutics Inc. (NASDAQ: SMMT) presents a compelling investment opportunity due to its innovative oncology pipeline, strategic collaborations, and strong market momentum.

The company’s lead candidate, ivonescimab, a bispecific antibody targeting PD-1 and VEGF, has shown promising results in Phase III clinical trials for non-small cell lung cancer, outperforming Merck’s Keytruda in head-to-head studies.

Summit’s partnership with Pfizer to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for treating solid tumors further enhances its growth prospects. Financially, the company maintains a debt-free balance sheet with total shareholder equity of $388.7 million.

These factors collectively position Summit Therapeutics for sustained growth and long-term value creation in the evolving biotechnology landscape.

Chart:

Get more picks like Summit…

If you are interested in receiving more of our top stock picks like Summit sign up to our Elite Membership where you get access to:

• 3 curated emails a week (monday, wednesday, friday) with 2 hand-picked Elite stocks in each email

• 1 report a week (sunday) on the general market and state of where the stock market is it currently

• Direct email contact with myself to ask any questions regarding stock knowledge

• Exclusive offers from any of our partners (trade software, brokers, news sources, etc.)

• 2 week money back guarantee (100% refund)

Join today for only $19.99/month or $199.99/year. 

Otherwise, stay tuned for our next free release at 8:15 am EST (Monday and Friday).

OUR RECENT ELITE TRADES ^{(updated Mar 12/25)}

If you invested $10,000 in each of these stocks you’d be sitting on:

$58,340

In less than 2 months...

Join Crown Elite today for only $19.99/month or $199.99/year

and get our Elite Picks Emailed to you every Monday, Wednesday and Friday.

Our Partners:

The #1 Trading Software in the world: Tradingview 

Thank you for your time!

I’m sure you get hundreds of emails a day so I thank you for taking the time to read ours. Please follow us on our social media channels below where we post other new and different content related to investing, personal finance, and trading. 

Stay tuned for our next free release at 8:15 am EST (Monday and Friday).